Kiora Pharmaceuticals has secured an exclusive license from Japan’s Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral drug candidate aimed at protecting nerve cells. The deal gives Kiora rights across most of the world for ophthalmology uses, while excluding certain countries, including countries in Asia.
Kiora will lead and fund development in its licensed territory. The agreement also covers development and commercialization of a companion diagnostic tool for glaucoma.
Key details
- KIO-401 is a small-molecule calpain inhibitor described as neuroprotective and late-stage. The license covers its development, manufacture and commercialization in ophthalmology.
- Kiora’s license is exclusive and sublicensable, but does not include certain specified countries, including countries in Asia.
- Kiora will pay Senju $3.5 million upfront. A further payment in the low tens of millions of dollars is due after technology transfer; part of that payment may be credited against future milestones.
- Senju is also eligible for up to $168.5 million in payments tied to regulatory and commercial milestones.
- Kiora will pay Senju royalties in the single digits as a percentage of KIO-401 net sales in the territory. The royalty rate may be adjusted in certain circumstances.
- Kiora has sole responsibility and decision-making authority for development in its territory, and will bear the associated costs.
- The agreement took effect on October 5, 2026, and was signed on October 23.
Plain-English implications
Kiora is taking on the development costs and responsibility for advancing KIO-401 in its territory in exchange for exclusive commercialization rights. The stated payments beyond the $3.5 million upfront amount depend on technology transfer, regulatory and commercial milestones, and product sales.